159 related articles for article (PubMed ID: 1322029)
21. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Haskel EJ; Prager NA; Sobel BE; Abendschein DR
Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
[TBL] [Abstract][Full Text] [Related]
22. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Martin U; Dörge L; Fischer S
Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
[TBL] [Abstract][Full Text] [Related]
23. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
Longridge DJ; Follenfant MJ; Ford AJ
Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
[TBL] [Abstract][Full Text] [Related]
24. Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Werier J; Ducas J; Gu S; Chan SM; Prewitt RM
Chest; 1991 Aug; 100(2):464-9. PubMed ID: 1650681
[TBL] [Abstract][Full Text] [Related]
25. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
[TBL] [Abstract][Full Text] [Related]
26. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
Mehta JL; Nichols WW; Saldeen TG; Chandna VK; Nicolini FA; Lawson DL; ter Riet MF
J Cardiovasc Pharmacol; 1990 Jul; 16(1):112-20. PubMed ID: 1696653
[TBL] [Abstract][Full Text] [Related]
27. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
Yasuda T; Gold HK; Yaoita H; Leinbach RC; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
J Am Coll Cardiol; 1990 Sep; 16(3):714-22. PubMed ID: 2117620
[TBL] [Abstract][Full Text] [Related]
28. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
Nicolini FA; Lee P; Malycky JL; Lefkovits J; Kottke-Marchant K; Plow EF; Topol EJ
Blood Coagul Fibrinolysis; 1996 Jan; 7(1):39-48. PubMed ID: 8845461
[TBL] [Abstract][Full Text] [Related]
29. Intravenous administration of recombinant tissue plasminogen activator. Optimizing the rate of coronary thrombolysis.
Prewitt RM; Gu S; Schick U; Ducas J
Chest; 1995 Apr; 107(4):1146-51. PubMed ID: 7705128
[TBL] [Abstract][Full Text] [Related]
30. Coronary thrombolysis with recombinant tissue plasminogen activator. Intracoronary vs intravenous administration.
Gu SA; Ducas J; Wolfe K; Patton JN; Prewitt RM
Chest; 1991 Jul; 100(1):201-6. PubMed ID: 1905615
[TBL] [Abstract][Full Text] [Related]
31. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.
Nicolini FA; Nichols WW; Mehta JL; Saldeen TG; Schofield R; Ross M; Player DW; Pohl GB; Mattsson C
J Am Coll Cardiol; 1992 Jul; 20(1):228-35. PubMed ID: 1607530
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
[TBL] [Abstract][Full Text] [Related]
33. Effect of rate of administration of recombinant tissue plasminogen activator on efficacy of coronary thrombolysis.
Prewitt RM; Gu S; Schick U; Ducas J
Angiology; 1994 Aug; 45(8):687-94. PubMed ID: 8048778
[TBL] [Abstract][Full Text] [Related]
34. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
Yasuda T; Gold HK; Leinbach RC; Saito T; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
[TBL] [Abstract][Full Text] [Related]
35. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
Saitoh S; Saito T; Otake A; Owada T; Mitsugi M; Hashimoto H; Maruyama Y
Arterioscler Thromb; 1993 Apr; 13(4):563-70. PubMed ID: 8385480
[TBL] [Abstract][Full Text] [Related]
36. Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
Gu S; Ducas J; Patton JN; Greenberg D; Prewitt RM
Chest; 1992 Jun; 101(6):1684-90. PubMed ID: 1600792
[TBL] [Abstract][Full Text] [Related]
37. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
[TBL] [Abstract][Full Text] [Related]
38. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis.
Martin U; Sponer G; Strein K
Int J Hematol; 1992 Oct; 56(2):143-53. PubMed ID: 1421176
[TBL] [Abstract][Full Text] [Related]
39. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
[TBL] [Abstract][Full Text] [Related]
40. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
